Patent intelligence · US
US 12090126
Methods of administering solriamfetol to lactating women
Methods of administering solriamfetol to lactating women
Patent details — US 12090126
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2024
- Expiration
- Sep 12, 2044
- Applicant
- AXSOME MALTA LTD.
- Claims
- 15
- CPC classes
- A61K, A61K31/165
Quick answer
US 12090126 (Methods of administering solriamfetol to lactating women) is held by AXSOME MALTA LTD.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXSOME MALTA LTD.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/165
More from AXSOME MALTA LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12390419
Formulations of (R)-2-amino-3-phenylpropyl carbamate
granted -
US 12384743
Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
granted -
US 12370196
Pharmaceutical compositions comprising meloxicam
granted -
US 12357640
Pharmaceutical compositions comprising meloxicam
granted -
US 12357697
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12318362
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12268693
Pharmaceutical compositions comprising a tolfenamic acid
granted -
US 12263145
Methods of administering solriamfetol to lactating women
granted
Frequently asked questions
What is US patent 12090126?
US 12090126 (Methods of administering solriamfetol to lactating women) is held by AXSOME MALTA LTD.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12090126?
AXSOME MALTA LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 162 pharmaceutical patents for this assignee.
When does US 12090126 expire?
Our index shows an expiration date of Sep 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.